Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% ...
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ...
Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed ...
Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting ...
Morning Overview on MSN
Power stations are not generators. Here is how they differ
Power stations and generators are often mentioned in the same breath, but they occupy very different roles in the energy ...
Your body is an amazing biological machine and it s electric. Every heartbeat, thought, and movement depends on tiny electrical impulses running through your body. You might not feel them, but these ...
The study presents convincing quantitative evidence, supported by appropriate negative controls, for the presence of low-abundance glycine receptors (GlyRs) within inhibitory synapses in telencephalic ...
This correspondence between brain state and brain responsiveness (statedependent responses) is outlined at different scales from the cellular and circuit level, to the mesoscale and macroscale level.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback